NECLIFE.NS Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (29 apr 2024 @ 11:59):

Stats
Dagens volum	140 432
Gjennomsnittsvolum	1.59M
Markedsverdi	7.76B
EPS	INR0 ( 2024-02-13 )
Neste inntjeningsdato	( INR0 ) 2024-05-27
Last Dividend	INR0.0500 ( 2020-09-18 )
Next Dividend	INR0 ( N/A )
P/E	96.11
ATR14	INR0.0730 (0.21%)

Volum Korrelasjon

Lang: 0.06 (neutral)

Kort: -0.47 (neutral)

Signal:(59.815) Neutral

Nectar Lifesciences Korrelasjon

10 Mest positive korrelasjoner

10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Nectar Lifesciences Korrelasjon - Valuta/Råvare

-0.59
( weak negative )

-0.52
( weak negative )

0.00
( neutral )

-0.67
( moderate negative )

-0.71
( moderate negative )

0.53
( weak )

Nectar Lifesciences Økonomi

Annual	2022
Omsetning:	INR15.24B
Bruttogevinst:	INR3.64B (23.91 %)
EPS:	INR-1.080

FY	2022
Omsetning:	INR15.24B
Bruttogevinst:	INR3.64B (23.91 %)
EPS:	INR-1.080

FY	2022
Omsetning:	INR16.69B
Bruttogevinst:	INR2.99B (17.94 %)
EPS:	INR1.120

FY	2021
Omsetning:	INR15.43B
Bruttogevinst:	INR2.58B (16.69 %)
EPS:	INR-3.27

Financial Reports:

No articles found.

Nectar Lifesciences Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)

Nectar Lifesciences Dividend Information - Ex Dividend Junior

Dividend Sustainability Score: 1.879 - low (50.00%) | Divividend Growth Potential Score: 2.78 - No dividend growth expected in the near future

Information

First Dividend	INR0.100	2006-02-01
Last Dividend	INR0.0500	2020-09-18
Next Dividend	INR0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	16	--
Total Paid Out	INR1.900	--
Avg. Dividend % Per Year	0.05%	--
Score	1.38	--
Div. Sustainability Score	1.879
Div.Growth Potential Score	2.78
Div. Directional Score	2.33	--

Next Divdend (Est)
(2024-09-10)

INR0 Estimate 0.00 %

Dividend Stability

0.04 Very Bad

Dividend Score

1.38

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield
2006	INR0	0.00%
2007	INR0	0.00%
2008	INR0	0.00%
2009	INR0	0.00%
2010	INR0	0.00%
2011	INR0	0.00%
2012	INR0	0.00%
2013	INR0	0.00%
2014	INR0	0.00%
2015	INR0	0.00%
2016	INR0	0.00%
2017	INR0	0.00%
2018	INR0.0500	0.19%
2019	INR0.0500	0.24%
2020	INR0.100	0.81%
2021	INR0	0.00%
2022	INR0	0.00%
2023	INR0	0.00%
2024	INR0	0.00%

Dividend Commentary

The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for NSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend
TRIL.NS	Dividend Junior	2023-07-27	Sporadic	17	0.22%
PILANIINVS.NS	Dividend Junior	2023-08-29	Annually	13	0.56%
JKCEMENT.NS	Dividend Junior	2023-08-01	Annually	19	0.37%
DEVIT.NS	Dividend Junior	2023-09-22	Annually	8	0.28%
SMSPHARMA.NS	Ex Dividend Junior	2023-09-22	Annually	18	0.12%
MINDTECK.NS	Dividend Junior	2023-08-04	Sporadic	8	0.28%
HBSL.NS	Dividend Junior	2023-08-11	Sporadic	12	0.78%
BEPL.NS	Dividend King	2023-07-25	Semi-Annually	20	4.91%
RADICO.NS	Dividend Junior	2023-09-14	Annually	22	0.24%
KHAICHEM.NS	No Dividend Player	2023-07-21	Annually	5	0.32%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.00493	1.500	9.90	10.00	[0 - 0.5]
returnOnAssetsTTM	0	1.200	0	0	[0 - 0.3]
returnOnEquityTTM	0.00754	1.500	-1.027	-1.541	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	0	0.800	-5.00	-4.00	[1 - 3]
quickRatioTTM	0	0.800	-4.71	-3.76	[0.8 - 2.5]
cashRatioTTM	0	1.500	-1.111	-1.667	[0.2 - 2]
debtRatioTTM	0	-1.500	0	0	[0 - 0.6]
interestCoverageTTM	1.093	1.000	-0.706	-0.706	[3 - 30]
operatingCashFlowPerShareTTM	5.43	2.00	8.19	10.00	[0 - 30]
freeCashFlowPerShareTTM	5.43	2.00	7.29	10.00	[0 - 20]
debtEquityRatioTTM	0	-1.500	0	0	[0 - 2.5]
grossProfitMarginTTM	0.251	1.000	9.14	9.14	[0.2 - 0.8]
operatingProfitMarginTTM	0.0553	1.000	-0.893	-0.893	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0	1.000	-1.111	-1.111	[0.2 - 2]
assetTurnoverTTM	0	0.800	-3.33	-2.67	[0.5 - 2]
Total Score				1.879

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	98.74	1.000	0.127	0	[1 - 100]
returnOnEquityTTM	0.00754	2.50	-0.660	-1.541	[0.1 - 1.5]
freeCashFlowPerShareTTM	5.43	2.00	8.19	10.00	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	5.43	2.00	8.19	10.00	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	0.736	1.500	8.43	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.0746	1.000	-0.635	0	[0.1 - 0.5]
Total Score				2.78

Nectar Lifesciences

Nectar Lifesciences Limited manufactures and sells pharmaceutical products in India and internationally. The company offers contract research and manufacturing services, including process development and optimization, process scale up and validation, preparation and international submission of drug master files and certificates of suitability, multi kilo pilot plant production, bulk production, and chiral resolution; and chemical and analytical development, as well as analytical, manufacturing, and engineering consulting services. Its active pharmaceutical ingredients and intermediates comprise cefixime trihydrate, cefuroxime axetil, cefpodoxime proxetil, cefdinir, ceftriaxone sodium, cefotaxime sodium, cefuroxime sodium, ceftazidime, cefepime HCl, cephalothin, cefazolin sodium, cefprozil, cefoperzone sodium, cefpirome sulphate, and cefoxitin sodium. The company also offers contract manufacturing for finished dosage forms, such as tablets, capsules, dry powder oral suspensions, and granules and injectable for cephalosporins. In addition, it provides a range of diagnostics products; empty hard gelatin capsules; and menthol products. Nectar Lifesciences Limited was incorporated in 1995 and is headquartered in Chandigarh, India.